Possibilities of long-term effective treatment of idiopathic pulmonary arterial hypertension by replacing sildenafil with riociguat and using sequential combination therapy: case report

Modern pathogenetic therapy of idiopathic pulmonary arterial hypertension (IPAH), a severe life-threatening cardiovascular disease of unknown etiology, leads to a positive clinical effect due to reverse remodeling of the vessels of the microvasculature of the lungs. Highly effective drugs of specific therapy that act on the main targets of pathogenesis have now been introduced into clinical practice.

The presented clinical case of a patient with diagnosed in 2014 IPAH with an initial functional class III according to the WHO classification demonstrates high long-term efficacy and safety of specific therapy based on the use of the soluble guanylate cyclase stimulator riociguat for 5 years after replacing previous therapy with sildenafil with further implementation of the strategy of sequential combination therapy due to the addition of ambrisentan and selexipag.

1. Chazova I.E., Martynyuk T.V., Valieva Z.S., et al. Eurasian clinical guidelines on diagnosis and treatment of pulmonary hypertension. Eurasian heart journal. 2020;(1):78-122. (In Russ). https://doi.org/10.38109/2225-1685-2020-1-78-122

2. D’Alonzo G.E., Barst R.J., Ayres S.M., et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med. 1991; 115(5): 343-9. https://doi.org/10.7326/0003-4819-115-5-343

3. Taran I.N., Martynyuk T.V., Nakonechnikov S.N., Chazova I.Y. Innovation in pharmaceutical treatment of pulmonary arterial hypertension: stimulator of soluble gyanylate cyclase – riociguat. Eurasian heart journal. 2015;(4):12-19. (In Russ.). https://doi.org/10.38109/2225-1685-2015-4-12-19

4. Chazova I.E., Martynyuk T.V. Riociguatas the first innovative guanylatecyclase stimulators class drugs for pulmonary arterial hypertension patients treatment. Systemic Hypertension. 2013;10(4):70-75 (In Russ.). https://doi.org/10.26442/SG28994

5. Shmal’ts A.A., Gorbachevskiy S.V. Riociguat and sildenafil for pulmonary hypertension: similarity and difference. Pulmonologiya. 2016;26(1):85-91. (In Russ.). https://doi.org/10.18093/0869-0189-2016-26-1-85-91

6. Hoeper M.M., Simonneau G., Corris P.A., et al. RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors. Eur Respir J. 2017;50:1602425. https://doi.org/10.1183/13993003.02425-2016

7. Rubin L.J., Galie N., Grimminger F., et al. Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2). Eur Respir J. 2015;45(5):1303-1313. https://doi.org/10.1183/09031936.00090614

8. Marra A.M., Halank M., Benjamin N., et al. Right ventricular size and function under riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (the RIVER study). Respir Res. 2018; 19 (1): 258. https://doi.org/10.1186/s12931-018-0957-y

9. Momoi M., Hiraide T., Shinya Y., et al. Triple oral combination therapy with macitentan, riociguat, and selexipag for pulmonary arterial hypertension. Ther Adv in Respir Disease. 2021; 15: 175346662199504. https://doi.org/10.1177/1753466621995048